JP2014502967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502967A5 JP2014502967A5 JP2013546430A JP2013546430A JP2014502967A5 JP 2014502967 A5 JP2014502967 A5 JP 2014502967A5 JP 2013546430 A JP2013546430 A JP 2013546430A JP 2013546430 A JP2013546430 A JP 2013546430A JP 2014502967 A5 JP2014502967 A5 JP 2014502967A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- binding protein
- amino acid
- acid substitution
- generation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014914 Carrier Proteins Human genes 0.000 claims 17
- 108091008324 binding proteins Proteins 0.000 claims 17
- 108010002350 Interleukin-2 Proteins 0.000 claims 14
- 102000000588 Interleukin-2 Human genes 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 10
- 102220427331 c.274A>T Human genes 0.000 claims 9
- 102200142011 rs121909050 Human genes 0.000 claims 9
- 102200131576 rs121912452 Human genes 0.000 claims 9
- 102200158049 rs387906619 Human genes 0.000 claims 9
- 102200005671 rs1013940 Human genes 0.000 claims 5
- 102200004150 rs147750704 Human genes 0.000 claims 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 3
- 102220606633 Zinc finger protein GLIS1_Q74N_mutation Human genes 0.000 claims 3
- 238000010494 dissociation reaction Methods 0.000 claims 3
- 230000005593 dissociations Effects 0.000 claims 3
- 102220058213 rs730881465 Human genes 0.000 claims 2
- 108700004922 F42A Proteins 0.000 claims 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 claims 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 claims 1
- 102000008193 Interleukin-2 Receptor beta Subunit Human genes 0.000 claims 1
- 108010060632 Interleukin-2 Receptor beta Subunit Proteins 0.000 claims 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102220234588 rs1114167484 Human genes 0.000 claims 1
- 102200032604 rs5030773 Human genes 0.000 claims 1
- 102220281620 rs551111938 Human genes 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426307P | 2010-12-22 | 2010-12-22 | |
| US61/426,307 | 2010-12-22 | ||
| PCT/US2011/066911 WO2012088446A1 (en) | 2010-12-22 | 2011-12-22 | Superagonists and antagonists of interleukin-2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016199322A Division JP6441867B2 (ja) | 2010-12-22 | 2016-10-07 | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502967A JP2014502967A (ja) | 2014-02-06 |
| JP2014502967A5 true JP2014502967A5 (enExample) | 2017-01-05 |
| JP6093712B2 JP6093712B2 (ja) | 2017-03-08 |
Family
ID=46314487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546430A Active JP6093712B2 (ja) | 2010-12-22 | 2011-12-22 | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
| JP2016199322A Active JP6441867B2 (ja) | 2010-12-22 | 2016-10-07 | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016199322A Active JP6441867B2 (ja) | 2010-12-22 | 2016-10-07 | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9428567B2 (enExample) |
| EP (2) | EP2655409A4 (enExample) |
| JP (2) | JP6093712B2 (enExample) |
| CA (1) | CA2860170C (enExample) |
| WO (1) | WO2012088446A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860170C (en) * | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| JP6445434B2 (ja) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン |
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| WO2014100014A1 (en) * | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-2 complexes with antibody to augment il-2 therapy |
| CN105722860A (zh) * | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015042706A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR102821381B1 (ko) | 2015-10-30 | 2025-06-13 | 캔써 리서치 테크놀로지 리미티드 | 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| WO2018089420A1 (en) | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| WO2018119114A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| CA3055200A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| WO2018170168A1 (en) | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| IL322312A (en) | 2017-08-03 | 2025-09-01 | Synthorx Inc | Cytokine conjugates for the treatment of infectious diseases and cell proliferation |
| KR20200064085A (ko) * | 2017-09-07 | 2020-06-05 | 큐 바이오파마, 인크. | 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| AU2018347796B2 (en) | 2017-10-10 | 2025-07-24 | Medicenna Therapeutics, Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| PH12020550661A1 (en) * | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR102684426B1 (ko) * | 2017-12-06 | 2024-07-11 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| WO2019239213A2 (en) * | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| KR20210025522A (ko) | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| JP7550745B2 (ja) | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Ｉｌ２アゴニスト |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
| BR112021008461A2 (pt) | 2018-11-08 | 2021-08-03 | Gammadelta Therapeutics Ltd | métodos para isolamento e expansão de células |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| WO2020163782A2 (en) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
| JP2022520632A (ja) | 2019-02-15 | 2022-03-31 | インテグラル・モレキュラー・インコーポレイテッド | 共通軽鎖を含む抗体及びその使用 |
| JP7570338B2 (ja) | 2019-02-15 | 2024-10-21 | インテグラル・モレキュラー・インコーポレイテッド | クローディン６抗体及びその使用 |
| CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
| US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| AU2020329290A1 (en) * | 2019-08-13 | 2022-03-24 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta agonists |
| WO2021055697A2 (en) * | 2019-09-18 | 2021-03-25 | The Regents Of The University Of California | Immunoactive microparticles and uses thereof |
| CN114502736A (zh) | 2019-10-11 | 2022-05-13 | 蒂尔坦生物制药有限公司 | 编码白介素-2变体(vIL-2)多肽的溶瘤病毒载体 |
| US12091440B2 (en) | 2019-12-20 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | IL2 and peptide-MHC complex fusion proteins and methods of use thereof |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CN121319219A (zh) * | 2020-01-14 | 2026-01-13 | 辛德凯因股份有限公司 | Il2突变蛋白 |
| CN115362168A (zh) * | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| IL295811A (en) * | 2020-03-05 | 2022-10-01 | Univ Leland Stanford Junior | designed variants of il-2 |
| AU2021202825B2 (en) | 2020-03-31 | 2022-06-30 | Hanmi Pharm. Co., Ltd. | Novel immunostimulating IL-2 analogs |
| CA3176515A1 (en) | 2020-04-22 | 2021-10-28 | Merck Sharp & Dohme Llc | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer |
| GB202006989D0 (en) | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| CN116096405A (zh) | 2020-05-12 | 2023-05-09 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| MX2022014082A (es) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
| US20230242607A1 (en) * | 2020-07-09 | 2023-08-03 | Eutilex Co., Ltd. | Il-2 variants |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| GB202105113D0 (en) | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CA3224147A1 (en) | 2021-07-09 | 2023-01-12 | Vijaya Raghavan PATTABIRAMAN | Antibody conjugates and manufacture thereof |
| WO2023281484A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
| AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
| EP4499846A1 (en) | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| GB202204926D0 (en) | 2022-04-04 | 2022-05-18 | Gammadelta Therapeutics Ltd | Method for expanding gammadelta T cells |
| US20250250329A1 (en) * | 2022-04-11 | 2025-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine adaptor proteins and uses thereof |
| KR20250114330A (ko) | 2022-11-30 | 2025-07-29 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식 |
| CN120529914A (zh) | 2023-01-09 | 2025-08-22 | 奥德赛治疗股份有限公司 | 抗tnfr2抗原结合蛋白及其用途 |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816249A (en) | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| US4738927A (en) | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4470461A (en) | 1982-09-30 | 1984-09-11 | Phillips Petroleum Company | Organic nitro compounds as cosurfactants in enhanced oil recovery processes |
| US5068177A (en) | 1983-12-28 | 1991-11-26 | Scripps Clinic And Research Foundation | Anti-idiotype antibodies induced by synthetic polypeptides |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
| NZ234674A (en) | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1994009820A1 (en) | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PL202058B1 (pl) | 1999-08-09 | 2009-05-29 | Merck Patent Gmbh | Wielofunkcyjne białko fuzyjne cytokin i przeciwciała |
| ATE354655T1 (de) | 1999-08-24 | 2007-03-15 | Medarex Inc | Humane antikörper gegen ctla-4 und deren verwendungen |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU7756100A (en) * | 1999-10-08 | 2001-04-23 | Curagen Corporation | Interleukin-2 like protein and nucleic acids encoding same |
| DE60035124T2 (de) | 1999-11-15 | 2008-02-07 | Onyx Pharmaceuticals, Inc., Emeryville | Ein oncolytisches adenovirus |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| PL206975B1 (pl) | 2001-12-04 | 2010-10-29 | Merck Patent Gmbh | Immunocytokiny o modulowanej selektywności oraz ich zastosowanie |
| US6894527B1 (en) | 2003-05-12 | 2005-05-17 | Xilinx, Inc. | Evolved circuits for bitstream protection |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007527242A (ja) | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP2008528621A (ja) * | 2005-01-27 | 2008-07-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 腎細胞ガンを処置するための方法 |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2622504A1 (en) | 2005-09-09 | 2008-03-08 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting cell death or enhancing cel proliferation |
| WO2009046104A1 (en) | 2007-10-01 | 2009-04-09 | University Of Miami | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
| EP2057972A1 (en) | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine deposit |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20100183545A1 (en) | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| EP4331604B9 (en) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2382228B2 (en) | 2009-01-21 | 2026-01-07 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| MX2011008697A (es) | 2009-02-17 | 2011-11-18 | Ucb Pharma Sa | Moleculas de anticuerpos que tiene especificidad para ox40 humano. |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| NZ602892A (en) | 2010-04-13 | 2014-08-29 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
| MY177065A (en) | 2010-09-09 | 2020-09-03 | Pfizer | 4-1bb binding molecules |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| US20160354472A1 (en) | 2010-10-22 | 2016-12-08 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| CA2860170C (en) * | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| FI20115914A7 (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| WO2014047350A1 (en) | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US9810692B2 (en) | 2012-10-26 | 2017-11-07 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
| KR102332790B1 (ko) | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| KR20160030936A (ko) | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| US10711272B2 (en) | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
| US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
| EP3834838A1 (en) | 2014-02-21 | 2021-06-16 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody |
| EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| AU2015308527C1 (en) | 2014-08-29 | 2021-07-15 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
| CA2969870A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| TW201639888A (zh) | 2015-03-06 | 2016-11-16 | 索倫多醫療公司 | 結合ｔｉｍ３之抗體治療劑 |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| JP6754532B2 (ja) | 2015-03-17 | 2020-09-16 | ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 |
| WO2017040790A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| HK1257931A1 (zh) | 2015-12-10 | 2019-11-01 | Definiens Ag | 治疗和选择对免疫介导的癌症治疗有反应的患者的方法 |
| BR112018067458A2 (pt) | 2016-03-04 | 2019-01-02 | Abmuno Therapeutics Llc | anticorpos para tigit |
-
2011
- 2011-12-22 CA CA2860170A patent/CA2860170C/en active Active
- 2011-12-22 US US13/997,503 patent/US9428567B2/en active Active
- 2011-12-22 EP EP11851134.4A patent/EP2655409A4/en not_active Withdrawn
- 2011-12-22 WO PCT/US2011/066911 patent/WO2012088446A1/en not_active Ceased
- 2011-12-22 JP JP2013546430A patent/JP6093712B2/ja active Active
- 2011-12-22 EP EP16205861.4A patent/EP3211001B1/en active Active
-
2016
- 2016-07-22 US US15/217,416 patent/US10183980B2/en active Active
- 2016-10-07 JP JP2016199322A patent/JP6441867B2/ja active Active
-
2018
- 2018-12-13 US US16/219,786 patent/US11117943B2/en active Active
-
2021
- 2021-09-09 US US17/470,246 patent/US12006347B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502967A5 (enExample) | ||
| JP2017008109A5 (enExample) | ||
| Iwaszko et al. | Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis | |
| Lazarevic et al. | T-bet: a bridge between innate and adaptive immunity | |
| Liao et al. | Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression | |
| Liao et al. | Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages | |
| JP6475712B2 (ja) | サイトカインアンタゴニストの標的化 | |
| CN112105633A (zh) | 新型白介素2及其用途 | |
| Hudson et al. | Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists | |
| Castro et al. | The basis of distinctive IL-2–and IL-15–dependent signaling: Weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development | |
| US11462297B2 (en) | Selective peptide antagonists | |
| JP2013530929A5 (enExample) | ||
| Su et al. | LTBP4 in Health and Disease | |
| JP2007507544A5 (enExample) | ||
| Kubick et al. | Interleukins and interleukin receptors evolutionary history and origin in relation to CD4+ T cell evolution | |
| NO20091235L (no) | Antagonistiske humane lysspesifikke monoklonale antistoffer | |
| RU2016140189A (ru) | Библиотеки tcr | |
| JP2013527765A5 (enExample) | ||
| EP2769992A3 (en) | High affinity human antibodies to human IL-4 receptor | |
| JP2009261399A5 (enExample) | ||
| AR083310A1 (es) | ANTICUERPOS ANTI-IL12Rb1 Y SU USO PARA TRATAR LOS TRASTORNOS AUTOINMUNES E INFLAMATORIOS | |
| JP2013535190A5 (enExample) | ||
| Guo et al. | Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region | |
| de Moura et al. | Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22 | |
| Sahoo et al. | Interleukin and interleukin receptor diversity: role of alternative splicing |